Shareholders of Bio-Rad Laboratories, Inc. (NYSE:BIO) will be pleased this week, given that the stock price is up 15% to US$368 following its latest third-quarter results. Overall the results were a little better than the analysts were expecting, with revenues beating forecasts by 3.4%to hit US$650m. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

View our latest analysis for Bio-Rad Laboratories

Taking into account the latest results, the most recent consensus for Bio-Rad Laboratories from six analysts is for revenues of US$2.68b in 2025. If met, it would imply a reasonable 3.9% increase on its revenue over the past 12 months. Earnings are expected to improve, with Bio-Rad Laboratories forecast to report a statutory profit of US$9.60 per share. In the lead-up to this report, the analysts had been modelling revenues of US$2.69b and earnings per share (EPS) of US$18.12 in 2025. So there's definitely been a decline in sentiment after the latest results, noting the large cut to new EPS forecasts.

The consensus price target held steady at US$399, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Bio-Rad Laboratories at US$469 per share, while the most bearish prices it at US$315. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Bio-Rad Laboratories' past performance and to peers in the same industry. The analysts are definitely expecting Bio-Rad Laboratories' growth to accelerate, with the forecast 3.1% annualised growth to the end of 2025 ranking favourably alongside historical growth of 2.5% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.5% per year. So it's clear that despite the acceleration in growth, Bio-Rad Laboratories is expected to grow meaningfully slower than the industry average.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Bio-Rad Laboratories. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Bio-Rad Laboratories. Long-term earnings power is much more important than next year's profits. We have forecasts for Bio-Rad Laboratories going out to 2026, and you can see them free on our platform here.

We also provide an overview of the Bio-Rad Laboratories Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.